Article
Oncology
Aleksandra Wieczorek, Anna Zaniewska-Tekieli, Karoline Ehlert, Katarzyna Pawinska-Wasikowska, Walentyna Balwierz, Holger Lode
Summary: Prognosis is poor for children with refractory and relapsed high-risk neuroblastoma. Chemotherapy combined with anti-GD2 antibodies has been shown to increase response and survival rates.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Holger N. Lode, Karoline Ehlert, Stephanie Huber, Sascha Troschke-Meurer, Nikolai Siebert, Maxi Zumpe, Hans Loibner, Ruth Ladenstein
Summary: Long-term continuous infusion of single-agent dinutuximab beta showed a 26% objective response rate in patients with relapsed/refractory high-risk neuroblastoma, with a three-year progression-free survival rate of 31% and overall survival rate of 66%. Adverse events such as pain, diarrhea, and hypokalemia were manageable, indicating the tolerability of this treatment approach.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Talha Badar, Aniko Szabo, Shira Dinner, Michaela Liedtke, Madelyn Burkart, Rory M. Shallis, Ilana R. Yurkiewicz, Eric Kuo, Muhammad Ali Khan, Suresh Balasubramanian, Jay Yang, Mehrdad Hefazi, Nikolai Podoltsev, Anand Patel, Emily Curran, Amy Wang, Shukaib Arslan, Ibrahim Aldoss, Caitlin Siebenaller, Ryan J. Mattison, Mark R. Litzow, Martha Wadleigh, Anjali S. Advani, Ehab Atallah
Summary: A study comparing the efficacy of blinatumomab and InO as first or second NA therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia found that the two agents may have comparable efficacy in this setting.
Article
Oncology
Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
Summary: This study analyzed the efficacy and safety of combining immunotherapy with dinutuximab beta and chemotherapy in patients with relapsed/refractory high-risk neuroblastoma. The results showed that this treatment approach had promising response rates in these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jia Zhu, Juan Wang, Feifei Sun, Zijun Zhen, Tingting Chen, Suying Lu, Junting Huang, Yizhuo Zhang, Xiaofei Sun
Summary: The combination of vincristine, irinotecan, and temozolomide is an effective salvage regimen for relapsed or refractory neuroblastoma patients, achieving a response rate of 69.6% with manageable toxicities.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Juan Wang, Lian Zhang, Lanying Guo, Yi Que, Yu Zhang, Feifei Sun, Jia Zhu, Suying Lu, Junting Huang, Liuhong Wu, Ruiqing Cai, Zijun Zhen, Sihui Zeng, Yizhuo Zhang, Xiaofei Sun
Summary: The combination of irinotecan and doxorubicin hydrochloride liposome regimens shows positive efficacy and well-tolerated toxicity in treating relapsed or refractory pediatric Wilms tumor. Further prospective clinical trials are warranted to validate these findings.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Benjamin J. Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D. Weiss, Michelle Choe, Jennifer H. Foster, Navin Pinto, Daniel A. Morgenstern, Margarida Simao Rafael, Keri A. Streby, Rachel N. Zeno, Rajen Mody, Sahr Yazdani, Ami Desai, Margaret E. Macy, Suzanne Shusterman, Sara M. Federico, Rochelle Bagatell
Summary: This study focuses on the timing, duration, and evolution of response after I/T/DIN/GM-CSF therapy in children with relapsed HRNB. It found that approximately half of the patients had objective responses, with a substantial improvement in patients with MR/PR on initial evaluation. The treatment was associated with extended PFS in responders both during and after discontinuation.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Masayuki Imaya, Hideki Muramatsu, Atsushi Narita, Ayako Yamamori, Manabu Wakamatsu, Taro Yoshida, Shunsuke Miwata, Kotaro Narita, Daisuke Ichikawa, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Nobuhiro Nishio, Seiji Kojima, Yoshiyuki Takahashi
Summary: This study retrospectively analyzed the therapeutic response and toxicity of IREC in patients with refractory or relapsed neuroblastoma. The results showed an objective response rate of 15% and good tolerability of IREC in these patients. UGT1A1 gene polymorphisms had an impact on the toxicity of IREC.
Article
Medicine, General & Internal
Aleksandra Wieczorek, Urszula Zebrowska, Marek Ussowicz, Agnieszka Sokol, Marzena Stypinska, Bozenna Dembowska-Baginska, Katarzyna Pawinska-Wasikowska, Walentyna Balwierz, Giuseppina Barutello
Summary: A retrospective study conducted in Poland demonstrated the feasibility and benefits of using Dinutuximab beta for maintenance treatment in patients with high-risk neuroblastoma. The overall survival and progression-free survival rates were high, and the treatment was generally well tolerated.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Martin J. Edelman, Mikhail Dvorkin, Konstatin Laktionov, Alejandro Navarro, Oscar Juan-Vidal, Vadim Kozlov, Gil Golden, Odette Jordan, C. Q. Deng, Dmitriy Bentsion, Christos Chouaid, Hristo Dechev, Afshin Dowlati, Natalia Fernandez Nunez, Olexandr Ivashchuk, Ivane Kiladze, Tsira Kortua, Natasha Leighl, Aleksandr Luft, Tamta Makharadze, YoungJoo Min, Xavier Quantin
Summary: The combination of dinutuximab/irinotecan did not show improved overall survival in patients with relapsed/refractory small cell lung cancer (SCLC) compared to irinotecan alone. Irinotecan administered every 21 days demonstrated comparable activity to topotecan administered daily x 5 every 21 days.
Editorial Material
Hematology
Pietro Merli
Summary: The report highlights the importance of pursuing a curative approach to improve prognosis in childhood acute myeloid leukemia.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Naval G. Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen W. L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G. Ott, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff
Summary: This phase 1b trial evaluated the use of venetoclax-idasanutlin in patients with relapsed/refractory acute myeloid leukemia ineligible for cytotoxic chemotherapy. The trial showed that venetoclax-idasanutlin is a feasible and effective treatment option for these patients, with manageable safety profile.
Article
Oncology
Jacob P. Laubach, Sascha A. Tuchman, Jacalyn M. Rosenblatt, Constantine S. Mitsiades, Kathleen Colson, Kelly Masone, Diane Warren, Robert A. Redd, Dena Grayson, Paul G. Richardson
Summary: The phase 1b study demonstrated the potential of Pano-RVd treatment for relapsed and refractory multiple myeloma, showing promise in overcoming lenalidomide and/or bortezomib resistance.
BLOOD CANCER JOURNAL
(2021)
Article
Hematology
Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Steve Serrao, Pejman Solaimani, Lihua Elizabeth Budde, Matthew G. Mei, Leslie L. Popplewell, Tanya Siddiqi, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, V. Alexey Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam
Summary: The ZUMA-7 study demonstrated that second-line axicabtagene ciloleucel improved event-free survival in patients with relapsed/refractory DLBCL. However, its cost-effectiveness is highly dependent on long-term outcomes, and the routine use of this therapy will significantly increase healthcare expenditures.
Article
Oncology
Mark A. Dawson, Gautam Borthakur, Brian J. P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria -Victoria Mateos, Natalia Tovar, Paul Yeh, Regina Garcia Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Summary: Molibresib, a selective inhibitor of BET proteins, was evaluated as a monotherapy for hematological malignancies. The study consisted of dose escalation to determine the recommended dose and dose expansion to assess safety and efficacy in relapsed/refractory MDS and CTCL patients. Results showed limited antitumor activity and significant toxicities, suggesting the need for combination regimens with molibresib.
CLINICAL CANCER RESEARCH
(2023)
